COVID-19 preclinical drug development database

Exscientia-Diamond-Scripps Partnership

Exscientia

Added 15/05/2020 | Updated 15/05/2020

Project Details

Type of project

  • Tier 1: repurposing existing medicines
  • Tier 2: testing existing molecules
  • Tier 3: discovering and categorising new molecules

Therapeutic target

  • Preventing infection (prophylaxis or preventing cell entry)
  • Preventing virus replication in early disease
  • Direct acting antiviral
  • Preventing cytokine release syndrome (immunomodulation or suppression)
  • Preventing death (respiratory failure, shock or multiple organ failure)

Type of supporting technology

Phase of project

  • High throughput screening
  • PK/PD testing and toxicology

Modality (if can be disclosed)*

  • Small molecule

Molecular/cellular target (if known or can be disclosed)*

  • ACE2
  • SARS-CoV-2 main protease
  • SARS-CoV-2 Spike protein
  • NSP12, PLPro

Partner institutions/organisations

  • Diamond Light Source
  • Scripps Institute

Key contact

Name: Martin Redhead

Email Address: mredhead@exscientia.co.uk

Phone Number:

Key Collaborators:

Anticipated timeframe of future outputs

1-3 months

This research project is looking for the following:

Animal Models

Further Details

Abstract or additional information (if available)*

https://www.drugtargetreview.com/news/59188/ai-technology-to-screen-existing-drugs-for-use-against-covid-19/

Published outputs (if available)*